Researchers at the University of Rochester Medical Center have identified a potential new neuromarker for juvenile-onset Batten disease, also known as CLN3 disease. The progressive, inherited disorder of the nervous system is characterized by vision loss, cognitive impairment, seizures, and a decline in motor skills. Finding reliable ways to measure the disease's progression has historically been challenging, complicating the evaluation of new treatments in clinical trials.
In a recent study, scientists utilized electroencephalography (EEG) to measure the brain activity of participants with and without Batten disease. The participants passively listened to simple auditory beeps while watching a video. The results demonstrated a clear decline in the response from the auditory sensory memory system in participants with Batten disease as their condition progressed, whereas no significant changes were observed in the control group.
This discovery is particularly significant because it provides an objective, non-invasive method to assess brain function without requiring active engagement or attention from the patient. This is crucial for populations with varying communication abilities. The researchers believe this easy-to-measure brain process could serve as a vital biomarker for measuring treatment outcomes in future clinical trials.
The team is now leveraging these findings to study Batten disease mouse models, aiming to measure the impact of various pharmaceuticals on the auditory perceptual system. By screening treatments already on the market for other conditions, they hope to quickly identify therapies that can positively alter the disease's dynamics. This advancement marks a critical step forward in the mission to evaluate the effectiveness of experimental treatments for this devastating childhood disorder.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.